AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Key Opinion Leader Perspectives of Perceptions of Lupus Pipeline Therapy Data Presented at EULAR, 2018 Report - ResearchAndMarkets.com

February 26, 2019

DUBLIN--(BUSINESS WIRE)--Feb 26, 2019--The “KOL Perspectives: Perceptions of Lupus Pipeline Therapy Data Presented at EULAR 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This KOL Insight briefing focuses on KOLs views of Pipeline Therapy Data Presented at EULAR 2018.

Questions topics

Key Highlights

Scope

In total, we conducted interviews with 10 KOLs

KOL data is analyzed to produce

Reasons to Buy

Key Topics Covered:

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5x6llf/key_opinion?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190226005550/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Musculoskeletal Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/26/2019 05:51 AM/DISC: 02/26/2019 05:51 AM

http://www.businesswire.com/news/home/20190226005550/en

All contents © copyright 2019 The Associated Press. All rights reserved.